ATE383355T1 - Polymorph und andere kristallinische formen von zusammen-ftc - Google Patents

Polymorph und andere kristallinische formen von zusammen-ftc

Info

Publication number
ATE383355T1
ATE383355T1 AT05076347T AT05076347T ATE383355T1 AT E383355 T1 ATE383355 T1 AT E383355T1 AT 05076347 T AT05076347 T AT 05076347T AT 05076347 T AT05076347 T AT 05076347T AT E383355 T1 ATE383355 T1 AT E383355T1
Authority
AT
Austria
Prior art keywords
ftc
forms
cis
manufacture
polymorphous
Prior art date
Application number
AT05076347T
Other languages
English (en)
Inventor
Kenneth R Phares
Devalina Law
Yuerong Hu
Original Assignee
Abbott Lab
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab, Gilead Sciences Inc filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE383355T1 publication Critical patent/ATE383355T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT05076347T 2001-03-01 2002-03-01 Polymorph und andere kristallinische formen von zusammen-ftc ATE383355T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27256001P 2001-03-01 2001-03-01
US30960501P 2001-08-02 2001-08-02

Publications (1)

Publication Number Publication Date
ATE383355T1 true ATE383355T1 (de) 2008-01-15

Family

ID=26955597

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05076347T ATE383355T1 (de) 2001-03-01 2002-03-01 Polymorph und andere kristallinische formen von zusammen-ftc
AT02748367T ATE312097T1 (de) 2001-03-01 2002-03-01 Polymorphe und andere kristalline formen von cis- ftc

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02748367T ATE312097T1 (de) 2001-03-01 2002-03-01 Polymorphe und andere kristalline formen von cis- ftc

Country Status (14)

Country Link
US (3) US6723728B2 (de)
EP (3) EP1389207B1 (de)
JP (4) JP5105689B2 (de)
KR (4) KR101150250B1 (de)
CN (4) CN102911166B (de)
AT (2) ATE383355T1 (de)
AU (1) AU2002335489B2 (de)
CA (4) CA2690137C (de)
CY (2) CY1107983T1 (de)
DE (2) DE60224592T2 (de)
DK (2) DK1389207T3 (de)
ES (3) ES2537007T3 (de)
PT (2) PT1903041E (de)
WO (1) WO2002070518A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE383355T1 (de) 2001-03-01 2008-01-15 Abbott Lab Polymorph und andere kristallinische formen von zusammen-ftc
TWI244393B (en) * 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
ES2308136T3 (es) 2003-01-14 2008-12-01 Gilead Sciences, Inc. Composiciones y procedimientos para la politerapia antiviral.
US6943249B2 (en) * 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US20060014949A1 (en) * 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
WO2009005338A2 (en) * 2007-07-05 2009-01-08 Ultimorphix Technologies B.V. Solid forms ult-i, ult-2 and ult-3 of emtricitabine
US20110288298A1 (en) 2008-11-12 2011-11-24 Lupin Limited novel polymorph of emtricitabine and a process for preparing of the same
WO2011007367A1 (en) 2009-07-15 2011-01-20 Lupin Limited An improved process for preparation of efavirenz

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4476248A (en) 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen
DE3485225D1 (de) 1983-08-18 1991-12-05 Beecham Group Plc Antivirale guanin-derivate.
US5684153A (en) 1984-08-16 1997-11-04 Beecham Group Plc Process for the preparation of purine derivatives
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
WO1989002733A1 (en) 1987-09-22 1989-04-06 The Regents Of The University Of California Liposomal nucleoside analogues for treating aids
NZ228645A (en) 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US6175008B1 (en) 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5041449A (en) 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US6346627B1 (en) 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5700937A (en) 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
AU7872491A (en) 1990-05-07 1991-11-27 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
EP0531452A4 (en) 1990-05-29 1993-06-09 Vical, Inc. Synthesis of glycerol di- and triphosphate derivatives
ES2083580T3 (es) 1990-06-13 1996-04-16 Arnold Glazier Profarmacos de fosforo.
US5674849A (en) 1990-10-24 1997-10-07 Allelix Biopharmaceuticals Inc. Anti-viral compositions
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US6228860B1 (en) * 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
US5179104A (en) 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5444063A (en) 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ250842A (en) * 1991-02-22 1996-03-26 Univ Emory Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc)
GB9104740D0 (en) 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
IT1244501B (it) 1991-03-22 1994-07-15 Sigma Tau Ind Farmaceuti Derivati amminoacilici e oligopeptidici dell'allopurinolo dotati di attivita' immunostimolante e composizioni farmaceutiche che li contengono
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
CA2112803A1 (en) 1991-07-12 1993-01-21 Karl Y. Hostetler Antiviral liponucleosides: treatment of hepatitis b
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
WO1994026273A1 (en) 1993-05-12 1994-11-24 Hostetler Karl Y Acyclovir derivatives for topical use
GB9311709D0 (en) 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
US5808040A (en) 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
SE503154C2 (sv) * 1995-03-10 1996-04-01 Tony Wiseby Anordning vid sikte för pilbåge
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
DE19543707A1 (de) * 1995-11-23 1997-05-28 Inst Neue Mat Gemein Gmbh Verfahren zum Konservieren von Papier
GB9525606D0 (en) 1995-12-14 1996-02-14 Iaf Biochem Int Method and compositions for the synthesis of dioxolane nucleosides with › - configuration
AU5127098A (en) 1996-11-29 1998-06-22 Smithkline Beecham Plc Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis
TW318283B (en) 1996-12-09 1997-10-21 United Microelectronics Corp Multi-level read only memory structure and manufacturing method thereof
DE69823984T2 (de) 1997-03-19 2005-05-12 University Of Georgia Research Foundation, Inc. Synthese, anti-hiv- und anti-hepatitis-b-virus-aktivitäten von 1,3-oxaselenolannukleosiden
EP2322518B1 (de) * 1998-08-12 2015-02-25 Gilead Sciences, Inc. Verfahren zur Herstellung von 1,3-Dioxolan- und 1,3-Oxathiolannukleosiden
CN101186937A (zh) 1998-10-09 2008-05-28 爱尔特斯制药公司 用于拆分对映体混合物的非均相体系
ATE383355T1 (de) 2001-03-01 2008-01-15 Abbott Lab Polymorph und andere kristallinische formen von zusammen-ftc
US6600044B2 (en) * 2001-06-18 2003-07-29 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers

Also Published As

Publication number Publication date
CN102911166B (zh) 2016-08-17
PT1574512E (pt) 2008-03-05
US6723728B2 (en) 2004-04-20
CA2788498A1 (en) 2002-09-12
CN102942563A (zh) 2013-02-27
JP5105689B2 (ja) 2012-12-26
PT1903041E (pt) 2015-06-23
ES2299950T3 (es) 2008-06-01
ES2537007T3 (es) 2015-06-01
EP1574512A1 (de) 2005-09-14
DE60224592T2 (de) 2009-01-29
CN102911166A (zh) 2013-02-06
EP1903041A3 (de) 2008-04-23
ES2253544T3 (es) 2006-06-01
DK1389207T3 (da) 2006-04-18
CY1107913T1 (el) 2013-09-04
CN1503796B (zh) 2012-07-04
US8637535B2 (en) 2014-01-28
US20050026934A1 (en) 2005-02-03
US20090306114A1 (en) 2009-12-10
CN102911165A (zh) 2013-02-06
CN102911165B (zh) 2016-08-17
KR20040002871A (ko) 2004-01-07
KR100927024B1 (ko) 2009-11-17
JP2015028045A (ja) 2015-02-12
US7544692B2 (en) 2009-06-09
DE60207850T2 (de) 2006-08-10
EP1389207A1 (de) 2004-02-18
KR101015510B1 (ko) 2011-02-16
JP2009197005A (ja) 2009-09-03
EP1574512B1 (de) 2008-01-09
JP2004530660A (ja) 2004-10-07
ATE312097T1 (de) 2005-12-15
CA2690137A1 (en) 2002-09-12
AU2002335489B2 (en) 2008-06-05
JP2013040192A (ja) 2013-02-28
CA2439831C (en) 2010-01-12
CA2867970A1 (en) 2002-09-12
EP1389207B1 (de) 2005-12-07
EP1903041B1 (de) 2015-02-18
CA2690137C (en) 2012-11-13
US20030060645A1 (en) 2003-03-27
KR20080065316A (ko) 2008-07-11
CA2788498C (en) 2016-02-16
WO2002070518A1 (en) 2002-09-12
DE60224592D1 (de) 2008-02-21
KR101150250B1 (ko) 2012-06-12
EP1903041A2 (de) 2008-03-26
KR20100091265A (ko) 2010-08-18
CA2439831A1 (en) 2002-09-12
CN1503796A (zh) 2004-06-09
DE60207850D1 (de) 2006-01-12
DK1574512T3 (da) 2008-03-03
CY1107983T1 (el) 2013-09-04
KR20080065317A (ko) 2008-07-11

Similar Documents

Publication Publication Date Title
CY1107913T1 (el) Πολυμορφικες και αλλες κρυσταλλικες μορφες cis-ftc
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
ZA200309887B (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
DE60137364D1 (de) Kristalline formen von atorvastatin
WO2002017358A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
HUP0402065A2 (hu) Heterobiciklikus szerkezetû hepatitis C vírus polimeráz inhibitorok, eljárás az elõállításukra és ezeket tartalmazó gyógyszerkészítmények
DE60330895D1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
MY147390A (en) Substituted isoindoles as bace inhibitors and their use
HK1112910A1 (en) Compounds and methods for the treatment or prevention of flavivirus infections
CY1110240T1 (el) Νεα παραγωγα 2η-πυριδαζινο-3-ονης, φαρμακευτικες συνθεσεις που τα περιεχουν και μεθοδος για την παρασκευη του δραστικου συστατικου
WO2007058583A3 (en) Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies
NZ609146A (en) Modified 4’-nucleosides as antiviral agents
WO2002016357A3 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
SE0102315D0 (sv) Compounds
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
WO2006100081A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
EA200701687A1 (ru) Гидрохлорид аморфного лерканидипина
MX2009013833A (es) Compuestos de piridazina cristalina.
MX2007011698A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
WO2005004805A3 (en) Thermally stable crystalline epirubicin hydrochloride and method of making the same
DE60310767D1 (de) PYRAZOL-3,4-d-PYRIMIDINDERIVATE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON H.PYLORI-INFEKTIONEN
ATE501153T1 (de) Kristallisation von festen formen von clopidogreladditionssalzen
JP2004500380A5 (de)
MY141583A (en) Novel fused heterocycles and uses thereof
RU93045711A (ru) Нейролептические пергидро-1h-пиридо(1,2-a)пиразины, способ их получения, фармацевтическая композиция, способ лечения

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1574512

Country of ref document: EP